XML 131 R107.htm IDEA: XBRL DOCUMENT
v3.20.4

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Segment Reporting Information [Line Items] |  |  |
Sales | $ 47,994 | $ 46,840 | $ 42,294
Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 47,747 | 46,319 | 42,151
Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 43,021 | 41,751 | 37,689
Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 14,380 | 11,084 | 7,171
Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 725 | 444 | 187
Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 580 | 404 | 149
Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 145 | 388 | 522
Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,938 | 3,737 | 3,151
Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,878 | 2,275 | 1,798
Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,087 | 926 | 907
Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 797 | 791 | 728
Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 170 | 238 | 239
Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,198 | 1,131 | 917
Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 329 | 662 | 742
Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 281 | 165 | 72
Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 251 | 273 | 265
Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 213 | 249 | 326
Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 211 | 263 | 496
Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 152 | 257 | 367
Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 130 | 121 | 87
Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 838 | 830 | 893
Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 330 | 411 | 582
Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 327 | 306 | 260
Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 857 | 975 | 1,140
Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 167 | 370 | 455
Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 482 | 590 | 857
Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 182 | 285 | 497
Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 453 | 391 | 347
Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 281 | 204 | 139
Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 220 | 215 | 190
Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,306 | 3,482 | 3,686
Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,971 | 2,041 | 2,228
Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 680 | 787 | 703
Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 236 | 879 | 902
Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 462 | 698 | 708
Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 386 | 442 | 453
Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 258 | 288 | 335
Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 218 | 293 | 376
Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 193 | 241 | 268
Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4,709 | 4,615 | 4,546
Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4,703 | 4,393 | 4,212
Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,939 | 2,784 | 2,630
Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,764 | 1,609 | 1,582
Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 23 | 175 | 250
Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 247 | 521 | 143
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 21,027 | 20,519 | 18,346
United States | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 20,956 | 20,433 | 18,228
United States | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 19,449 | 18,953 | 16,742
United States | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 8,352 | 6,305 | 4,150
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 417 | 269 | 127
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 359 | 239 | 95
United States | Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 18 | 183 | 312
United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,755 | 1,831 | 1,873
United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,378 | 1,683 | 1,430
United States | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 727 | 679 | 627
United States | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 486 | 506 | 496
United States | Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 103 | 130 | 127
United States | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 583 | 533 | 386
United States | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 42 | 282 | 353
United States | Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 119 | 84 | 46
United States | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2 | 2 | 7
United States | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 7 | 6 | 12
United States | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 9 | 30 | 253
United States | Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 46 | 92 | 191
United States | Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 74 | 63 | 42
United States | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 81 | 92 | 96
United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 326 | 398 | 513
United States | Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 60 | 118 | 8
United States | Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | (1) | 14 | 45
United States | Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 12 | 16 | 10
United States | Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 259 | 194 | 134
United States | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,470 | 1,724 | 1,969
United States | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 477 | 589 | 811
United States | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 488 | 568 | 495
United States | Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 110 | 742 | 722
United States | Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 18 | 29 | 20
United States | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 21 | 24 | 23
United States | Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 12 | 9 | 23
United States | Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 84 | 103 | 115
United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,555 | 1,416 | 1,231
United States | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,484 | 1,306 | 1,238
United States | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 612 | 582 | 528
United States | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 872 | 724 | 710
United States | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 23 | 174 | 248
United States | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 71 | 86 | 118
Int’l |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 26,967 | 26,321 | 23,949
Int’l | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 26,791 | 25,885 | 23,923
Int’l | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 23,572 | 22,798 | 20,947
Int’l | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 6,028 | 4,779 | 3,021
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 308 | 176 | 61
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima (1) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 220 | 165 | 54
Int’l | Operating Segments | Pharmaceutical segment | Emend |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 127 | 205 | 210
Int’l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,184 | 1,905 | 1,279
Int’l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 500 | 592 | 368
Int’l | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 359 | 247 | 281
Int’l | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 311 | 284 | 232
Int’l | Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 67 | 108 | 112
Int’l | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 615 | 598 | 531
Int’l | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 287 | 380 | 389
Int’l | Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 162 | 81 | 27
Int’l | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 248 | 271 | 258
Int’l | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 207 | 242 | 314
Int’l | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 202 | 233 | 243
Int’l | Operating Segments | Pharmaceutical segment | Cubicin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 106 | 165 | 176
Int’l | Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 56 | 58 | 45
Int’l | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 838 | 830 | 893
Int’l | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 330 | 411 | 582
Int’l | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 247 | 214 | 164
Int’l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 531 | 576 | 627
Int’l | Operating Segments | Pharmaceutical segment | Zepatier |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 107 | 252 | 447
Int’l | Operating Segments | Pharmaceutical segment | Zetia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 483 | 575 | 813
Int’l | Operating Segments | Pharmaceutical segment | Vytorin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 171 | 269 | 487
Int’l | Operating Segments | Pharmaceutical segment | Atozet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 453 | 391 | 347
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas (2) |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 22 | 10 | 5
Int’l | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 220 | 215 | 190
Int’l | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,836 | 1,758 | 1,718
Int’l | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,494 | 1,452 | 1,417
Int’l | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 192 | 219 | 208
Int’l | Operating Segments | Pharmaceutical segment | NuvaRing |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 127 | 136 | 180
Int’l | Operating Segments | Pharmaceutical segment | Singulair |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 444 | 669 | 688
Int’l | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 365 | 418 | 431
Int’l | Operating Segments | Pharmaceutical segment | Arcoxia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 258 | 288 | 335
Int’l | Operating Segments | Pharmaceutical segment | Nasonex |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 206 | 284 | 353
Int’l | Operating Segments | Pharmaceutical segment | Follistim AQ |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 109 | 138 | 153
Int’l | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,152 | 3,204 | 3,308
Int’l | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,219 | 3,086 | 2,974
Int’l | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,327 | 2,201 | 2,102
Int’l | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 892 | 885 | 872
Int’l | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 1 | 2
Int’l | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | $ 176 | $ 436 | $ 26

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |